MDAI ROSECLIFF ACQUISITION CORP I

Spectral AI Schedules 2023 Third Quarter Financial Results and Conference Call

Spectral AI Schedules 2023 Third Quarter Financial Results and Conference Call

DALLAS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 13, 2023 after the close of the stock market. The Company will host a conference call on Tuesday, November 14, 2023 at 9:00 am Eastern Time to discuss the results.

Investors interested in participating in the live call can dial:

  • 833-630-1956 - U.S.
  • 412-317-1837 - International

A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit .

Contacts:

Investors:

Spectral AI

Vince Capone  

General Counsel

 

The Equity Group

Devin Sullivan, Managing Director





Conor Rodriguez, Analyst

 

Media:

Russo Partners

David Schull

Russo Partners

(858) 717-2310

 

Guillermo Ruiz, M.D., Ph.D.

Russo Partners

(646) 218-4604



EN
01/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ROSECLIFF ACQUISITION CORP I

 PRESS RELEASE

Spectral AI Announces 2025 Second Quarter Financial Results

Spectral AI Announces 2025 Second Quarter Financial Results Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 MillionStrong Cash position of $10.5 MillionSubmission of De Novo application to FDA completed in Second Quarter of 2025 DALLAS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter e...

 PRESS RELEASE

Spectral AI Schedules 2025 Second Quarter Financial Results and Confer...

Spectral AI Schedules 2025 Second Quarter Financial Results and Conference Call DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System and focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 12, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the resul...

 PRESS RELEASE

Spectral AI Announces Submission to FDA of its DeepView® System

Spectral AI Announces Submission to FDA of its DeepView® System DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and artificial intelligence (“AI”) algorithms to predict burn healing potential, today announced the submission of its De Novo 510k marketing clearance application to the FDA for the DeepView System, intended for use in burn care settings, inclu...

 PRESS RELEASE

DeepView® System highlighted at the annual British Burn Association co...

DeepView® System highlighted at the annual British Burn Association conference DALLAS, June 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the annual British Burn Association (BBA) conference, held from June 4th – 6th in Brighton, UK. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the globe. Key Presentat...

 PRESS RELEASE

Spectral AI Announces Appointment of Stanley Micek as Chief Operating ...

Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company’s Chief Operating Officer (“COO”). Micek’s promotion reflects his role change from Interim COO of the Company since May, 2024 “Stan has demonstrated exceptional leadership, operational insight, and a deep unde...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch